Business Description
Addex Therapeutics Ltd
ISIN : CH0029850754
Total Employee Number:
3Compare
Compare
Traded in other countries / regions
ADXN.Switzerland0QNV.UKAPE.GermanyADXN.USA IPO Date
2007-05-24Description
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 9.2 | |||||
Equity-to-Asset | 0.69 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -108.64 | |||||
Beneish M-Score | -0.35 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 20.4 | |||||
3-Year EPS without NRI Growth Rate | 36.7 | |||||
3-Year FCF Growth Rate | 53.6 | |||||
3-Year Book Growth Rate | -14.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.32 | |||||
9-Day RSI | 40 | |||||
14-Day RSI | 42.47 | |||||
3-1 Month Momentum % | 43.08 | |||||
6-1 Month Momentum % | -15.45 | |||||
12-1 Month Momentum % | 29.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.97 | |||||
Quick Ratio | 0.97 | |||||
Cash Ratio | 0.77 | |||||
Days Sales Outstanding | 428.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.2 | |||||
Shareholder Yield % | -17.8 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -8960 | |||||
Net Margin % | -23223.33 | |||||
EBITDA Margin % | -23543.33 | |||||
FCF Margin % | -7884.38 | |||||
OCF Margin % | -7884.38 | |||||
ROE % | -118 | |||||
ROA % | -95.58 | |||||
ROIC % | -52.48 | |||||
3-Year ROIIC % | 195.45 | |||||
ROC (Joel Greenblatt) % | -14101.59 | |||||
ROCE % | -115.51 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.56 | |||||
Price-to-Tangible-Book | 1.23 | |||||
EV-to-EBIT | -0.82 | |||||
EV-to-EBITDA | -0.82 | |||||
EV-to-Revenue | 193.93 | |||||
EV-to-FCF | -2.49 | |||||
Price-to-GF-Value | 3.7 | |||||
Earnings Yield (Greenblatt) % | -121.95 | |||||
FCF Yield % | -35.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Addex Therapeutics Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.032 | ||
| EPS (TTM) (€) | -0.054 | ||
| Beta | 0.2345 | ||
| 3-Year Sharpe Ratio | -0.48 | ||
| 3-Year Sortino Ratio | -0.53 | ||
| Volatility % | 73.06 | ||
| 14-Day RSI | 42.47 | ||
| 14-Day ATR (€) | 0.002709 | ||
| 20-Day SMA (€) | 0.04195 | ||
| 12-1 Month Momentum % | 29.17 | ||
| 52-Week Range (€) | 0.031 - 0.081 | ||
| Shares Outstanding (Mil) | 151.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Addex Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Addex Therapeutics Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-12-04 10:00 | In 159 days | ||
| Third quarter earnings results for 2026 | 2026-12-04 | In 158 days | ||
| Second quarter earnings conference call for 2026 | 2026-10-01 10:00 | In 95 days | ||
| Second quarter earnings results for 2026 | 2026-10-01 | In 94 days | ||
| General meeting for 2026 | 2026-06-29 11:00 | In 1 day | ||
| First quarter earnings conference call for 2026 | 2026-06-25 10:00 | 0.04 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-06-25 | 0.04 (+0.00%) | ||
| Annual report for 2025 | 2026-05-15 | 0.05 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-04-30 10:00 | 0.05 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-30 | 0.05 (+0.00%) |
Show
Entries
Addex Therapeutics Ltd Frequently Asked Questions
What is Addex Therapeutics Ltd(FRA:APE)'s stock price today?
The current price of FRA:APE is €0.04. The 52 week high of FRA:APE is €0.08 and 52 week low is €0.03.
When is next earnings date of Addex Therapeutics Ltd(FRA:APE)?
The next earnings date of Addex Therapeutics Ltd(FRA:APE) is 2026-10-01 Est..
Does Addex Therapeutics Ltd(FRA:APE) pay dividends? If so, how much?
Addex Therapeutics Ltd(FRA:APE) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Thinking about buying stock in Applovin, Sonos, WiMi Hologram Cloud, Addex Therapeutics, or Snap? | 2023-02-09 | ||
| Enamine Extend Collaboration With Prominent Swiss Biotech | 2021-02-24 |
Articles on Addex Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers